share_log

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20

Benzinga ·  Dec 20 19:29  · Ratings

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $30 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment